Arcutis Biotherapeutics, Inc.

Listed Company

ARQTCIK 0001787306NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$376.07M

Net Income

$-16.14M

Total Assets

$432.97M

Equity

$189.48M

Shares Out

125.08M

Op. Cash Flow

$-5.63M

ARQT$28.46+83.79% · past yearDBEQ Basic

Daily closing prices

Business

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company developing and commercializing topical and systemic treatments for immune-mediated dermatological diseases. The company's lead product, ZORYVE (roflumilast), a PDE4 inhibitor, is approved for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis across multiple age groups and formulations (cream and foam). Arcutis commercializes ZORYVE in the United States and Canada through its specialty sales force, with partnerships for development and commercialization in Japan, Greater China, and Southeast Asia. The pipeline includes ARQ-234, a CD200R checkpoint agonist acquired via the Ducentis acquisition, under development for atopic dermatitis and other inflammatory conditions.

Summary from 10-K filed 2026-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Product revenue, net	372	167	29	4	0
Other revenue	4	30	30	0	—
Total revenues	376	197	60	4	—
Cost of sales	37	19	5	754,000	0
Research and development	77	76	111	182	146
Selling, general and administrative	275	229	185	122	61
Total operating expenses	388	325	301	305	207
Loss from operations	−12	−128	−241	−302	−207
Interest income	9	16	13	—	—
Interest expense	−12	−27	−30	−16	—
Other income (expense), net	443,000	47,000	−731,000	6	173,000
Loss before income taxes	−15	−139	−259	−311	−206
Provision for income taxes	1	600,000	3	0	0
Net loss	−16	−140	−262	−311	−206
Unrealized gain on marketable securities	−206,000	219,000	1	−831,000	−253,000
Foreign currency translation adjustment	169,000	−230,000	−96,000	0	0
Total other comprehensive income (loss)	−37,000	−11,000	1	−831,000	−253,000
Comprehensive loss	−16	−140	−261	−312	−207
Net loss per share, basic (in USD per share)	−0.13	−1.16	−3.78	−5.66	−4.18
Net loss per share, diluted (in USD per share)	−0.13	−1.16	−3.78	−5.66	−4.18
Weighted-average shares used in computing net loss per share, basic (in shares)	127	121	69	55	49
Weighted-average shares used in computing net loss per share, diluted (in shares)	127	121	69	55	49

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	43	71	88	54	—
Restricted cash	308,000	617,000	900,000	1	2
Marketable securities	178	157	183	356	291
Trade receivables, net	146	73	26	8	0
Inventory	23	15	13	8	0
Prepaid expenses and other current assets	21	20	19	11	14
Total current assets	411	336	330	437	403
Property, plant, and equipment, net	1	1	2	2	2
Intangible assets, net	15	9	6	7	0
Operating lease right-of-use asset	4	2	2	3	3
Other assets	1	596,000	596,000	78,000	78,000
Total assets	433	349	341	449	408
Accounts payable	13	14	12	9	7
Current portion of long-term debt, net	1	0	—	—	—
Accrued and other current liabilities	116	67	34	28	26
Total current liabilities	130	81	47	38	33
Operating lease liability, long-term	5	3	3	4	5
Long-term debt, net	108	107	202	198	72
Other long-term liabilities	431,000	570,000	849,000	0	25,000
Total liabilities	243	191	253	240	110
Commitments and contingencies (Note 8)	—	—	—	—	—
Common stock, $0.0001 par value; 300,000,000 shares authorized; 123,332,672 and 117,848,033 shares issued and outstanding at December 31, 2025 and 2024, respectively	12,000	12,000	9,000	6,000	5,000
Additional paid-in capital	1,328	1,279	1,071	930	706
Accumulated other comprehensive loss	−44,000	−7,000	4,000	−1	−255,000
Accumulated deficit	−1,138	−1,122	−982	−720	−408
Total stockholders equity	189	158	89	210	298
Total liabilities and stockholders equity	433	349	341	449	408

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	40	42	39	33	24
Amortization of intangible assets	5	2	750,000	312,000	0
Non-cash interest expense	2	5	4	3	—
Net accretion on marketable securities	−2	−7	−7	−2	3
Other non-cash items, net	652,000	769,000	2	—	—
Accounts receivable, net	−73	−47	−17	−8	0
Inventories	−7	−400,000	−6	−8	0
Prepaid expenses and other current assets	−2	−948,000	−9	3	−7
Accounts payable	−2	2	3	2	245,000
Accrued liabilities	50	32	6	1	10
Operating lease liabilities	−680,000	−735,000	−657,000	−433,000	243,000
Net cash used in operating activities	−6	−112	−247	−258	−175
Purchases of marketable securities	−247	−255	−226	−415	−293
Proceeds from maturities and sales of marketable securities	227	289	407	—	—
Purchases of property and equipment	−686,000	−143,000	−428,000	−333,000	−995,000
Milestone payment for intangible asset	−10	−5	0	−8	0
Net cash provided by (used in) investing activities	−30	29	180	−87	−76
Proceeds from issuance of common stock, net of issuance costs	0	162	0	162	207
Repayment of long-term debt	0	−100	0	0	—
Proceeds from issuance of common stock upon exercise of stock options	5	3	1	1	1
Proceeds from issuance of common stock for ESPP	2	2	1	2	842,000
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs	0	0	96	0	0
Proceeds from issuance of shares under ATM, net of issuance costs	0	0	3	14	0
Net cash provided by financing activities	7	66	101	302	282
Effect of exchange rate changes on cash	168,000	−235,000	−50,000	0	0
Net increase (decrease) in cash, cash equivalents and restricted cash	−29	−17	34	−43	31
Right-of-use assets obtained in exchange for operating lease liabilities	3	0	0	0	0
Interest expense paid in cash	10	22	25	13	142,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Arcutis Biotherapeutics, Inc.'s CIK number?

Arcutis Biotherapeutics, Inc.'s SEC CIK number is 0001787306 (1787306). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Arcutis Biotherapeutics, Inc.'s SEC filings?

All of Arcutis Biotherapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Arcutis Biotherapeutics, Inc. last report earnings?

Arcutis Biotherapeutics, Inc. (ARQT) most recently filed an earnings 8-K with the SEC on Feb 25, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001787306-26-000017). This is Arcutis Biotherapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Arcutis Biotherapeutics, Inc.'s most recent earnings 8-K?

Arcutis Biotherapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Feb 25, 2026 under accession 0001787306-26-000017. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Arcutis Biotherapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →